Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

In this Discussion

Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.

    Support MFO

  • Donate through PayPal

Doctors say treatment using anti-parasite drug gave 'astounding' results

edited May 23 in Off-Topic

Coronavirus: Bangladesh doctors say treatment using anti-parasite drug gave 'astounding' results
A Bangladeshi medical team combined Ivermectin -- generally used for de-worming and as a treatment against head lice and scabies -- with the antibiotic Doxycycline to treat infections.

Not HCQ nor many's favorite remdesivir
But ivermectin...who figures
Data could be too early but several countries/USA States are starting to use them as first line. We may come up with seversl cocktails to treat covid19 by next fall after reviewing anecdotal datas and studies from past 5 6 months



  • edited May 23
    NEJM findings

    Remdesivir for the Treatment of Covid-19 — Preliminary Report



    Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious.


    We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.


    A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%).


    Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 number, NCT04280705. opens in new tab.)

    we may have two horses race now Remdesivir and Ivermectin
  • As I posted in another thread (regarding the SEC segregating personally identifiable information from a transaction tracking database), any press release should IMHO be read with a skeptical eye.

    In the case of the ivermectin/doxycycline combo, all reports appear to be sourced from a single newswire story, with gushing quotes from the doctor leading the medical team.
    We have got astounding results. Out of 60 COVID-19 patients, all recovered ...

    [Dr.] Alam ... said a frequently used antiprotozoal medicine called Ivermectin in a single dose with Doxycycline, an antibiotic, yielded virtually the near-miraculous result in curing the patients with COVID-19.

    all of them have shown remarkable recovery being (COVID-19) negative in four days and 50 per cent reduction of symptoms in 3 days, he said.

    Alam's associate Dr Rabiul Morshed said despite being a non-COVID-19 facility a huge number of patients directly and indirectly end up in BMCH, the country's premier private general hospital.
    That last claim, about Bangladesh Medical College Hospital, may be accurate. "Bangladesh Medical College Hospital is one of the pinnacle and the first private medical college hospitals in Bangladesh, providing services at an affordable cost."

    Funds for Treatment of Hospitalized Patients: Evidence from Bangladesh, J Health Popul Nutr. 2014 Sep; 32(3): 465–470.

    With respect to recovery, there is no mention of a control group. That should have been easy, given that, as quoted above, "a huge number of [COVID-19] patients ... end up in BMCH.

    The patients receiving the cocktail may all have had relatively mild cases. This is suggested by the fact that they weren't tested upon admission but only later: "most of them initially reporting with respiratory problems with related complaints, later to be tested COVID-19 positive, he said."

    An Australian study just published is entitled The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. That's just evidence that the drug might also be efficacious in vivo. (The paper notes that it has shown positive results in mice with pseudorabies.)

    As observed in the abstract, "Ivermectin therefore warrants further investigation for possible benefits in humans."

    The race is not among horses, but against time. Unless one is looking to make a fast buck by picking the right "horse".
  • you can turn any healthcare page once you hit the adjective 'astounding'
Sign In or Register to comment.